Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma. In the 921-patient trial, twice-daily 45

Read the full 415 word article

User Sign In